HS Pipeline Watch: Abbvie’s Lutikizumab Advances to Phase 3 in HS

Adults with moderate to severe hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy showed higher response rates in Hidradenitis Suppurativa Clinical Response 50 (HiSCR) at week 16 when treated with lutikizumab (ABT-981) 300 mg every other week or 300 mg compared to patients who received placebo, according to results from a new Phase 2 study. […]

Study: DermTech’s Melanoma Test Can Rule Out the Cancer in Real-World Settings

DermTech, Inc.’s Melanoma Test (DMT) performed well in a real-world clinical setting, the Company reports. The test assesses pigmented skin lesions, moles or dark skin spots for melanoma. In particular, the PLA detects expression of the LINC00518 (LINC) and preferentially expressed antigen in melanoma (PRAME) genes using reverse transcription-polymerase chain reaction (RT-PCR). The Company introduced […]

TDD’s Guide to Maui Derm Caribbean 2024; Stay Tuned for Daily Coverage

Approaching its second year, the Maui Derm Caribbean meeting is slated to take place at the Hilton Aruba from January 10–13, 2024. Led by Louisville, KY dermatologist Joe Fowler, MD, and George Martin, MD, a dermatologist in Kihei, HI, and Maui Derm Program Chairman, the four-day meeting will feature treatment updates on psoriasis, atopic dermatitis, acne/rosacea, pigmentation […]

ChatGPT Can Provide Reliable Information on AD

Large language models like Chat-Generative Pre-Trained Transformer (ChatGPT) have become novel resources for patients, especially as physicians struggle to keep up with the unsustainable number of electronic messages and questions they get from their patients. It turns out that Chat-GPT may be a reliable resource and supplement to physician-dispensed advice on atopic dermatitis (AD), according […]

IPC Adds to Board of Directors

André Vicente Esteves de Carvalho, MD, PhD, and Amy Paller, MS, MD, are the newest members of the International Psoriasis Council’s (IPC) volunteer Board of Directors. Dr. Carvalho is responsible for the Psoriasis Ambulatory and a researcher at the Hospital Moinhos de Vento Complexo in Porto Alegre, Brazil.  Dr. Paller is the Walter J. Hamlin Professor […]

And Then There Were Two: FDA Approves Zelsuvmi for Molluscum Contagiosum

The U.S. Food and Drug Administration (FDA) has approved Zelsuvmi (berdazimer topical gel, 10.3%) for the treatment of molluscum contagiosum in adults and children one year of age and older. Zelsuvmi is expected to be commercially available during the second half of 2024, according to Ligand Pharmaceuticals. Zelsuvmi is the first novel drug for the treatment of molluscum infections […]

Last Patient Dosed in Part 2 of Verrica’s Phase 2 Study of VP-315 in BCC 

The last patient has been dosed in Part 2 of Verrica Pharmaceuticals Inc.’s Phase 2 trial of VP-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. VP-315 is a chemotherapeutic administered intratumorally. It works by inducing lysis of intracellular organelles of tumor cells such as mitochondria, thereby unleashing a broad spectrum of […]

Rosacea Pipeline Watch: Journey Medical Submits NDA for DFD-29 

Journey Medical Corporation has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults.  DFD-29 is being developed in collaboration with Dr. Reddy’s Laboratories Ltd. “Based on the […]

Vaping Linked to AD, PsO, Burns, and More

Tremendous attention has been paid to the detrimental effects of e-cigarettes on lung tissue, but less is known about how e-cigarette use affects the skin. To find out more, researchers culled the literature to better define the dermatological burden of e-cigarettes and vaping. Here’s what they found: Vaping and AD: What’s the link? Smoking is […]